| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/08/2023 | 1934.17% | HC Wainwright & Co. | → $2.5 | Initiates Coverage On | → Buy |
What is the target price for ZyVersa Therapeutics (ZVSA)?
The latest price target for ZyVersa Therapeutics (NASDAQ: ZVSA) was reported by HC Wainwright & Co. on September 8, 2023. The analyst firm set a price target for $2.50 expecting ZVSA to rise to within 12 months (a possible 1934.17% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ZyVersa Therapeutics (ZVSA)?
The latest analyst rating for ZyVersa Therapeutics (NASDAQ: ZVSA) was provided by HC Wainwright & Co., and ZyVersa Therapeutics initiated their buy rating.
When is the next analyst rating going to be posted or updated for ZyVersa Therapeutics (ZVSA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ZyVersa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ZyVersa Therapeutics was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.
Is the Analyst Rating ZyVersa Therapeutics (ZVSA) correct?
While ratings are subjective and will change, the latest ZyVersa Therapeutics (ZVSA) rating was a initiated with a price target of $0.00 to $2.50. The current price ZyVersa Therapeutics (ZVSA) is trading at is $0.12, which is within the analyst's predicted range.